RegenETP Past Earnings Performance
Past criteria checks 0/6
RegenETP has been growing earnings at an average annual rate of 34.6%, while the Biotechs industry saw earnings growing at 16.9% annually. Revenues have been growing at an average rate of 6.9% per year.
Key information
34.6%
Earnings growth rate
58.0%
EPS growth rate
Biotechs Industry Growth | -14.6% |
Revenue growth rate | 6.9% |
Return on equity | -66.9% |
Net Margin | -11,376.7% |
Last Earnings Update | 31 Mar 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How RegenETP makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 23 | 0 | -8 | 11 | 10 |
31 Dec 22 | 1 | -8 | 15 | 11 |
30 Sep 22 | 2 | -16 | 18 | 12 |
30 Jun 22 | 3 | -13 | 19 | 13 |
31 Mar 22 | 5 | -17 | 22 | 15 |
31 Dec 21 | 9 | -30 | 23 | 14 |
30 Sep 21 | 12 | -32 | 25 | 13 |
30 Jun 21 | 14 | -38 | 29 | 12 |
31 Mar 21 | 14 | -47 | 30 | 11 |
31 Dec 20 | 10 | -43 | 36 | 12 |
30 Sep 20 | 8 | -54 | 48 | 13 |
30 Jun 20 | 6 | -70 | 62 | 13 |
31 Mar 20 | 5 | -80 | 73 | 14 |
31 Dec 19 | 6 | -92 | 80 | 16 |
30 Sep 19 | 7 | -128 | 117 | 21 |
30 Jun 19 | 7 | -125 | 113 | 22 |
31 Mar 19 | 6 | -116 | 105 | 21 |
31 Dec 18 | 4 | -111 | 92 | 21 |
31 Oct 18 | 2 | -74 | 51 | 19 |
31 Jul 18 | 0 | -62 | 39 | 17 |
30 Apr 18 | 0 | -50 | 26 | 18 |
31 Jan 18 | 0 | -141 | 25 | 118 |
31 Oct 17 | 0 | -131 | 19 | 112 |
31 Jul 17 | 0 | -121 | 13 | 108 |
30 Apr 17 | -1 | -118 | 13 | 105 |
31 Jan 17 | -1 | -8 | 8 | 0 |
31 Oct 16 | 0 | -10 | 4 | 0 |
31 Jul 16 | 0 | -10 | 5 | 0 |
30 Apr 16 | 3 | -9 | 5 | 0 |
31 Jan 16 | 4 | -11 | 5 | 0 |
31 Oct 15 | 7 | -6 | 6 | 0 |
31 Jul 15 | 13 | -11 | 9 | 0 |
30 Apr 15 | 14 | -13 | 10 | 1 |
31 Jan 15 | 16 | -13 | 12 | 1 |
31 Oct 14 | 34 | -16 | 16 | 2 |
31 Jul 14 | 38 | -15 | 16 | 3 |
30 Apr 14 | 39 | -16 | 16 | 4 |
31 Jan 14 | 46 | -15 | 17 | 5 |
31 Oct 13 | 47 | -13 | 17 | 6 |
31 Jul 13 | 64 | -11 | 19 | 7 |
30 Apr 13 | 69 | -10 | 20 | 7 |
31 Jan 13 | 90 | -5 | 24 | 8 |
Quality Earnings: NJT is currently unprofitable.
Growing Profit Margin: NJT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NJT is unprofitable, but has reduced losses over the past 5 years at a rate of 34.6% per year.
Accelerating Growth: Unable to compare NJT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NJT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-26.8%).
Return on Equity
High ROE: NJT has a negative Return on Equity (-66.86%), as it is currently unprofitable.